Page last updated: 2024-08-24

valsartan and Nephritis

valsartan has been researched along with Nephritis in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Dong, J; Huang, D; Jing, L; Wu, M1
Bader, M; Baltatu, OC; Campos, LA; Louie, P; Schumacher, C; Zaugg, CE1
Abe, M; Baba, S; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Takashima, H; Yoshida, Y1
Hartner, A; Hilgers, KF; Mann, JF; Porst, M; Veelken, R1

Trials

1 trial(s) available for valsartan and Nephritis

ArticleYear
Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.
    Clinical and experimental nephrology, 2013, Volume: 17, Issue:3

    Topics: Adult; Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Female; Fumarates; Humans; Hypertension; Hypertension, Renal; Male; Middle Aged; Nephritis; Nephrosclerosis; Tetrazoles; Valine; Valsartan

2013

Other Studies

3 other study(ies) available for valsartan and Nephritis

ArticleYear
Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway.
    Analytical cellular pathology (Amsterdam), 2022, Volume: 2022

    Topics: Cholesterol, LDL; Glycosides; Humans; Interleukin-1beta; Interleukin-8; Nephritis; Toll-Like Receptor 4; Tripterygium; Valsartan

2022
Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
    Pharmacological research, 2014, Volume: 80

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Antihypertensive Agents; Diuresis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hematocrit; Humans; Hypertension, Renal; Kidney; Male; Nephritis; Pyridines; Pyrimidines; Rats; Rats, Transgenic; Renin; Tetrazoles; Valine; Valsartan

2014
Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation.
    Circulation, 2001, Sep-18, Volume: 104, Issue:12

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Malignant; Hypertension, Renovascular; Immunohistochemistry; Kidney; Macrophages; Male; Nephritis; Organ Size; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan

2001